4D Molecular Therapeutics

Following #ECFS2024, Jennifer Taylor-Cousar, M.D., #ClinicalTrial Principal Investigator, discussed the progress of the AEROW trial investigating 4DMT’s aerosolized 4D-710 gene therapy candidate for CFTR modulator-ineligible/-intolerant #cysticfibrosis (CF) lung disease.   Listen to Dr. Taylor-Cousar as she dives into the data she presented at the conference and shares an update on the trial’s next steps with CGTLive. https://lnkd.in/ePRDPtsc

#CEOSpotlight: The July issue of Drug Discovery News took a look at the history of oncolytic viral therapies and highlighted 4DMT Co-founder and CEO, David Kirn, MD's, contributions to this pioneering field. David’s groundbreaking work in #geneticengineering has opened new avenues in the field of virology. His innovative approach and dedication have significantly advanced the development of engineered viruses, showcasing the potential of genetic engineering in therapeutic applications.   Learn more about his remarkable journey and contributions to the field here: https://lnkd.in/ghi8Y6cP

Our Co-founder and CEO, David Kirn, MD, recently shared updates on 4DMT’s #retinal programs – including 4D-150 for #wetAMD and #DME, and 4D-175 for the treatment of #geographicatrophy – with Healio | Ocular Surgery News at CTS Retina.   David also provided insight into the next steps in developing these programs, with the initiation of the wet AMD Phase 3 #clinicaltrial expected in Q1 2025 and reporting Phase 2 clinical trial data in #DME later this year.   #ophthalmology

Age-related macular degeneration (AMD) affects the area where our sharpest vision occurs – our central vision. If you have AMD, you might find it challenging to see people’s faces, read, drive or take part in other daily activities. Compared to dry AMD #wetAMD generally causes more rapid and serious vision loss and may progress to blindness without treatment. These challenges may interfere with your social life and your sense of independence, making it harder to manage your daily needs and responsibilities. At 4DMT, we’re on a mission to unlock the full potential of genetic medicines for large market diseases like wet AMD. Learn more about our customized vector platform and wet AMD genetic medicine candidate: https://ow.ly/xn3i50Sv6XK

Last week, we gathered for our first in-person All Hands of the year. It was a fantastic opportunity to celebrate our achievements from 2024 thus far, including our 9th IND/CTA clearance since our first in 2018. Highlights included updates from our executive team on our #clinical progress, a look ahead to H2 milestones, a lively Q&A session and welcoming 26 new team members to #4DMT!   Thank you to everyone who made this event a success. Together, we continue to break boundaries and work as a team to prepare and execute relentlessly to reach our goals. Follow along as we continue this exciting journey.

#WetAMD is a type of macular degeneration where abnormal blood vessels (choroidal neovascularization or CNV) grow into the macula, the central area of the retina. As a result, CNV causes swelling and edema of the retina, bleeding and scarring, visual distortion and reduced visual acuity. Without treatment, this process can cause irreversible damage to central vision and potentially lead to blindness. Our lead clinical candidate, 4D-150, has the potential to significantly reduce treatment burden and control disease activity, revolutionizing the treatment approach for patients with wet AMD. Learn more about 4D-150: https://lnkd.in/gsyvT_a2

#ICYMI, our Co-founder and CEO, David Kirn, MD, was recently featured in a Newsweek and Investment Reports Q&A. David dives into 4DMT’s technology and proprietary Therapeutic Vector Evolution platform, our various models of partnership, and our ongoing #clinicaltrials. Check out it out: https://lnkd.in/gQEtiDf8

Our inspiring, innovative and collaborative environment thrives on our people, who contribute individually and grow their careers with us at 4DMT. This month, we asked Raja Vakil, our Sr. Director, Clinical Operations, what inspires him to come to work every day: #EmployeeSpotlight

Today, we announced the U.S. Food and Drug Administration (FDA) clearance of the Investigational New Drug Application (IND) for our R100 vector-based intravitreal #geneticmedicine, 4D-175, for the treatment of people living with #GeographicAtrophy (GA). The GAZE clinical trial will assess 4D-175 in patients with GA secondary to AMD. We are encouraged by the validation to date that supports our Therapeutic Vector Evolution platform, with over 150 patients treated with the next-generation R100 vector. Learn more about the news here: https://lnkd.in/eVbzWvMq #ophthalmology

#CysticFibrosis (CF) is a rare, progressive, #genetic disease that affects the lungs, pancreas and other organs. CF is a complex disease and the types of symptoms and severity can differ widely from person to person.    As people with CF live longer, their disease manifests in different ways, forcing them to confront new challenges related to life with the disease, including infections, CF-related diabetes, gastrointestinal issues, reproductive health, mental health and more.    We are committed to advancing potentially transformative therapies that slow or halt the progression of lung damage to benefit all people living with CF. Learn more: https://lnkd.in/giTk5Y9t